Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Interferon‐α alone vs interferon‐α plus bevacizumab

1‐year mortality · previously untreated patients with mRCC

Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1, 1.36]
2 studies · 1381 participants
Low

Interferon‐α alone vs standard targeted therapies

1‐year mortality · previously untreated patients with mRCC

Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.3 [1.13, 1.51]
2 studies · 1166 participants
Moderate